Table 1 Baseline Characteristics of the Included Studies
Study | Year | Country | Age | Sex | Sample size | Follow-up (months) | Cancer type | Outcome |
|---|---|---|---|---|---|---|---|---|
Sahn et al | 1988 | USA | 60.0 ± 1.9 | Mixed (53.33% male) | 60 | 37 | Mixed (not specified) | OS |
Panadero et al | 1989 | Spain | NA | NA | 50 | 28 | Pleural metastatic carcinoma | OS |
Foresti et al | 1990 | Italy | 64.8 ± 17.7 | Mixed (44.44% male) | 36 | 27 | Mixed (lung, breast, mesothelioma, and others) | OS |
Gottehrer et al | 1991 | USA | NA | NA | 26 | 7 | MPM | OS |
Sugiura et al | 1997 | Japan | NA | Mixed (67.51% male) | 62 | 54 | NSCLC | OS |
Moragón et al | 1998 | Spain | 60 ± 13 | Mixed (45% male) | 120 | median 9 | Mixed (NSCLC, breast, lymphoma, and others) | OS |
Burrows et al | 2000 | USA | 62(24–84) | Mixed (50% male) | 85 | 53 | Mixed (lung, breast, mesothelioma, and others) | OS |
Heffner et al | 2000 | USA | 61 ± 13 | Mixed (50% male) | 417 | 36 | Mixed (lung, breast, unknown primary, mesothelioma, and others) | OS |
Chen et al | 2001 | China | 67.9 ± 11.2 | Mixed (71.29% male) | 202 | 49 | Lung cancer | OS |
Thyle´n et al | 2001 | Sweden | NA | Mixed (97% male) | 100 | 100 | MPM | OS |
Bernard et al | 2002 | France | 65 ± 11 | Mixed (45.71% male) | 70 | > 3 | Mixed (breast, unknown, lung, and others) | OS |
Eitan et al | 2005 | USA | 55 (26–88) | NA | 97 | 150 | Optimally debulked ovarian carcinoma | PFS |
Aelony et al | 2006 | USA | NA | Mixed (92.31% male) | 26 | 18 | MPM | OS |
Aoe et al | 2006 | Japan | 69(22–95) | Mixed (72.55% male) | 102 | 22 | Lung cancer | OS |
Soh et al | 2006 | Japan | NA | Mixed (65.6% male) | 61 | 30 | Lung cancer | OS |
Bielsa et al | 2008 | Spain | 67 ± 13 | Mixed (52.82% male) | 284 | 40 | Mixed (lung, breast, unknown, and others) | OS |
Wu et al | 2008 | China | 63.4 (37.5–85.4) | Mixed (38.97% male) | 136 | 27 | Lung adenocarcinoma | OS |
Hsu et al | 2009 | China | 63(27–80) | Mixed (51.5% male) | 97 | 49 | NSCLC | OS |
Wu et al | 2009 | China | NA | Mixed (58.33% male) | 60 | 36 | Lung cancer | OS |
Kotyza et al | 2010 | Czech Republic | 63 ± 11 | Mixed (70.73% male) | 164 | 36 | Lung cancer | OS |
Lan et al | 2010 | China | 59 ± 16 | Mixed (55% male) | 44 | 36 | Mixed (lung, breast, hepatoma and others) | OS |
Ozyurtkan et al | 2010 | Turkey | 59 ± 14 | Mixed (56% male) | 85 | 52 | Mixed (mesothelioma, lung, ovary, breast, and others) | OS |
Pilling et al | 2010 | UK | 60 (26–89) | Mixed (38.85% male) | 278 | 71 | Mixed (breast, mesothelioma, lung, ovarian, and others) | OS |
Tanrikulu et al | 2010 | Turkey | NA | Mixed (59.8% male) | 363 | 54 | MPM | OS |
Hirayama et al | 2010 | Japan | 69.17 ± 9.64 | Mixed (82.6% male) | 54 | 20 | MPM | OS |
Park et al | 2011 | South Korea | 68.3 ± 15.0 | Mixed (65.67% male) | 67 | 36 | Lung cancer | OS |
Sakr et al | 2011 | France | Median 61 | Mixed (46.7% male) | 107 | 120 | Mixed (lung, melanoma, breast, ovarian and others) | OS |
Yamada et al | 2011 | Japan | 66.16 ± 10.05 | Mixed (68.9% male) | 45 | 73 | MPM | OS |
Guo et al | 2011 | China | 64.5 ± 9.8 | Mixed (53.13% male) | 128 | 28 | Lung adenocarcinoma | OS |
Hooper et al | 2012 | UK | 73(39–96) | Mixed (62.14% male) | 103 | 6 | Mixed (mesothelioma, lung, breast, ovarian, and others) | OS |
Maribel et al | 2012 | spain | 63(53.2–80.0) | Mixed (66.7% male) | 30 | 40 | Lung adenocarcinoma | OS |
Qian et al | 2012 | China | NA | Mixed (60.76% male) | 79 | 18 | Lung adenocarcinoma | OS |
Qian et al | 2012 | China | NA | Mixed (61% male) | 103 | 7 | Lung adenocarcinoma | PFS |
Wang et al | 2012 | China | NA | Mixed (41.85% male) | 184 | 29 | NSCLC | OS |
Cheng et al | 2013 | China | NA | Mixed (63.38% male) | 71 | 60 | Lung cancer | OS |
Faiz et al | 2013 | USA | 65(17–85) | Mixed (54.95% male) | 111 | 172 | Acute leukemia | OS |
Gorgun et al | 2013 | Turkey | 60.20 ± 13.91 | Mixed (57% male) | 51 | 27 | Mixed (lung, breast, pancreas, and others) | OS |
Park et al | 2013 | Korea | 68.3 ± 15.0 | Mixed (66.25% male) | 80 | 35 | Lung cancer | OS |
Wu et al | 2013 | China | 27.9–95.5 | Mixed (45.5% male) | 448 | 81 | Lung adenocarcinoma | OS |
Anevlavis et al | 2014 | Greece | 69 (37–93) | Mixed (53% male) | 90 | 56 | Mixed (breast, mesothelioma, gastrointestinal, and others) | OS |
Clive et al | 2014 | UK | 53–80 | Mixed (53.6% male) | 789 | 33 | Mixed (mesothelioma, hematological malignancy, gynecological malignancy, breast, and others) | OS |
Ni et al | 2014 | China | 31–81 | Mixed (47% male) | 75 | 45 | NSCLC | OS |
Xu et al | 2014 | China | 56.3 ± 12.5 | Mixed (46.15% male) | 78 | 16 | Lung cancer | OS |
Zhang et al | 2014 | China | 64(36–84) | Mixed (51% male) | 85 | 30 | NSCLC | OS |
Zhang et al | 2014 | China | Median 64 | Mixed (65.7% male) | 70 | 36 | Lung cancer | OS |
Abrao et al | 2015 | Brazil | 59.6 (11.8) | Mixed (29.07% male) | 86 | 1 | Mixed (lung, breast, gastrointestinal, and others) | OS |
Gkiozos et al | 2015 | Greece | NA | Mixed (75.2% male) | 40 | 44 | NSCLC | OS |
PFS | ||||||||
Porcel et al | 2015 | Spain | 58–78 | Mixed (77% male) | 556 | 30 | Lung cancer | OS |
Xu et al | 2015 | China | 58.3 ± 13.7 | Mixed (54.08% male) | 98 | 100 | Lung cancer | OS |
Zamboni et al | 2015 | Brazil | 60.0 (1.0–95.0) | Mixed (47% male) | 165 | 100 | Mixed (ovary, breast, lymphoma, lung, and others) | OS |
Zhao et al | 2015 | China | NA | Mixed (48.8% male) | 43 | 30 | Lung adenocarcinoma | PFS |
Abrao et al | 2016 | Brazil | 60 (24–86) | Mixed (31.25% male) | 64 | 6 | Mixed (lung, breast, gastrointestinal, and others) | OS |
Hsu et al | 2016 | China | Median 57 | Mixed (59% male) | 61 | 59 | Mixed (lung, breast, and others) | OS |
Kasapoglu et al | 2016 | Turkey | 64 (30–85) | Mixed (76% male) | 199 | 60 | Lung cancer | OS |
Psallidas et al | 2016 | UK | NA | NA | 75 | 28 | Mixed (not specified) | OS |
Tamiya et al | 2016 | Greece | 68 (49–83) | Mixed (69.9% male) | 23 | 47 | NSCLC | OS |
PFS | ||||||||
Terra et al | 2016 | USA | 58.9 ± 12 | Mixed (28.21% male) | 156 | 40 | Mixed (breast, lung, lymphoma, and others) | OS |
Usui et al | 2016 | Japan | NA | Mixed (80% male) | 25 | 50 | NSCLC | OS |
PFS | ||||||||
Verma et al | 2016 | Singapore | 71 (38–92) | Mixed (51% male) | 71 | 49 | Lung adenocarcinoma | OS |
Yang et al | 2016 | China | 38–75 | Mixed (48.7% male) | 78 | 32 | Lung cancer | OS |
Amn et al | 2017 | Indonesia | 17–85 | Mixed (44% male) | 102 | 27 | Mixed (lung, breast, lymphoma, and others) | OS |
Lee et al | 2017 | South Korea | NA | Mixed (51.3% male) | 158 | 72 | Lung cancer | OS |
Lu et al | 2017 | China | 59.34 ± 1.56 | Mixed (65.71% male) | 70 | 264 | NSCLC | OS |
Yang et al | 2017 | Korea | 71 (42–94) | Mixed (37.5% male) | 40 | 40 | Lung adenocarcinoma | PFS |
Zheng et al | 2017 | China | NA | Mixed (46.1% male) | 128 | 55 | NSCLC | OS |
PFS | ||||||||
Abisheganaden et al | 2018 | Singapore | 72(38–92) | Mixed (53% male) | 70 | 20 | Lung adenocarcinoma | OS |
Elena et al | 2018 | Spain | 61.6 ± 11.2 | Mixed (56% male) | 84 | 14 | Mixed (breast, mesothelioma, and lung cancer) | OS |
Han et al | 2018 | Korea | 70 ± 11 | Mixed (65% male) | 131 | 84 | Mixed (lung, breast, ovary, lymphoma, and others) | OS |
Jeba et al | 2018 | India | median 53 | Mixed (29% male) | 48 | 70 | Mixed (lung, breast, gastrointestinal, and others) | OS |
Lim et al | 2018 | Korea | 68(35–92) | Mixed (55.3% male) | 217 | 32 | NSCLC | OS |
PFS | ||||||||
Porcel et al | 2018 | Spain | 52–76 | Mixed (57% male) | 24 | 70 | diffuse large B-cell lymphomas | OS |
Psallidas et al | 2018 | UK | NA | NA | 232 | 133 | MPE | OS |
Wu et al | 2018 | China | 44(28–50) | Mixed (51% male) | 142 | 45 | Lung adenocarcinoma | OS |
Xu et al | 2018 | China | 62(40–78) | Mixed (50% male) | 40 | 43 | MPM | OS |
Foote et al | 2019 | USA | 61.44 ± 15.36 | Mixed (41% male) | 686 | 83 | Mixed (lung, breast, gynecologic, lymphoma, and others) | OS |
Kleontas et al | 2019 | United Kingdom | 61.0 ± 10.9 | Mixed (92.5% male) | 40 | 41 | Lung cancer | OS |
Tian et al | 2019 | China | 59.7 ± 9.12 | Mixed (46% male) | 160 | 25 | Mixed (lung, breast, esophageal, gastric, and mesothelioma) | OS |
Wang et al | 2019 | China | NA | Mixed (88% male) | 295 | 84 | Lung adenocarcinoma | OS |
Martin et al | 2020 | UK | 71(69–74) | Mixed (67% male) | 97 | 75 | Mixed (mesothelioma, lung, breast, genitourinary, and others) | OS |
Quek et al | 2020 | Singapore | 65(56–71) | Mixed (59% male) | 130 | 14 | Mixed (lung, mesothelioma, breast, gastrointestinal, and others) | OS |
Shi et al | 2020 | China | 65(55–73) | Mixed (51.3% male) | 193 | 65 | Mixed (lung, mesothelioma, and others) | OS |
Stockhammer et al | 2020 | Germany | 73.7 ± 8.6 | Mixed (88% male) | 48 | 40 | MPM | OS |